ensifentrine · Ohtuvayre

Small molecule

Also known as RPL554

Approvedregulatory verdict

Evidence outlook

Approved: Chronic Obstructive Pulmonary Disease

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

track record: Reliable signal

Also approved (2)
HK
  • Maintenance treatment of COPD in adult patients (1+ mechanism); release dated 2026-03-12
Product first approved 2026utusan.com.my
MO
  • Maintenance treatment of COPD in adult patients
Product first approved 2025utusan.com.my

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Chronic Obstructive Pulmonary Disease
NCT06460493 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2024-06-11 – 2024-12-03 · COPD
What this study did
Phase 2 (14)
Chronic Obstructive Pulmonary Disease
NCT05270525 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2022-05-27 – 2027-03-01 · Pulmonary Disease, Chronic Obstructive, COPD
What this study did
NCT07016412 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2025-07-31 – 2026-08-17 · Chronic Obstructive Pulmonary Disease
What this study did
NCT07132983 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2025-10-06 – 2025-11-28 · Chronic Obstructive Pulmonary Disease
What this study did
NCT04091360 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2019-04-29 – 2021-01-21 · COPD
What this study did
NCT03937479 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2019-05-01 – 2019-11-15 · COPD
What this study did
NCT04027439 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2018-12-10 – 2019-05-23 · Pulmonary Disease, Chronic Obstructive
What this study did
NCT03673670 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2018-07-16 – 2018-11-13 · COPD
What this study did
NCT03443414 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2017-06-01 – 2018-02-07 · COPD
What this study did
NCT03028142 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2017-01 – 2017-08 · Chronic Obstructive Pulmonary Disease Moderate
What this study did
NCT02542254 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2015-10 – 2015-12 · Chronic Obstructive Pulmonary Disease
What this study did
Other / comorbidity
NCT06559150 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2024-09-11 – 2027-09-24 · Non-cystic Fibrosis Bronchiectasis
What this study did
NCT04527471 · Verona Pharma Inc
2020-09-04 – 2021-05-01 · Coronavirus Infection, Covid-19, SARS-CoV-2
What this study did
NCT02919995 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2017-02-08 – 2017-11-03 · Cystic Fibrosis
What this study did
NCT02427165 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2015-04 – 2015-11 · Asthma
What this study did
Phase 1 (2)
Chronic Obstructive Pulmonary Disease
NCT05758428 · Nuance Pharma (shanghai) Co., Ltd
2023-03-06 – 2023-04-18 · Chronic Obstructive Pulmonary Disease
What this study did
NCT02307162 · Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
2014-12 – 2015-07 · Inflammatory Disorder of the Respiratory Tract, Chronic Obstructive Pulmonary Disorder
What this study did

Competitive landscape

3 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Chronic Obstructive Pulmonary Disease: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ensifentrine (Ohtuvayre): this drugApprovedSmall moleculePDE3/PDE4Reliable signal
NCT05743075: Placebo-corrected change from baseline in FEV1 AUC0-12h at Week 12: +110 mL for ensifentrine (p<0.0001)
NCT04535986: Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12 (Baseline (pre-dose on Day 1) and Week 12): Ensifentrine 0.0611 liters (Standard Error 0.01825) vs Placebo -0.0256 liters (Standard Error 0.0195)
Aclidinium Bromide (Tudorza Pressair)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT03022097: Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L.
NCT00891462: Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1) (Change from Baseline to 12 weeks): Aclidinium Bromide, 200µg 0.062 L (Standard Error 0.015) | Aclidinium Bromide, 400µg 0.099 L (Standard Error 0.015) vs Placebo -0.025 L (Standard Error 0.015)
Aclidinium Bromide / Formoterol Fumarate (Duaklir Pressair)
ApprovedUS marketing discontinued
Small moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptorPartial signal
NCT03022097: Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013)
NCT02796677: Week 24, AB/FF 400/12 ug: 1-hour post-dose FEV1 vs aclidinium 400 ug +0.084 L (95% CI 0.051 to 0.117), p<0.0001; trough FEV1 vs formoterol 12 ug +0.055 L (95% CI 0.023 to 0.088), p=0.0009. Monotherapy primary: aclidinium vs tiotropium trough FEV1 +0.007 L (95% CI -0.021 to 0.035), non-inferior at the -50 mL margin (CT.gov posted results).
Budesonide / Formoterol Fumarate (SYMBICORT)ApprovedCombinationGlucocorticoid receptor; Beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere)ApprovedSmall moleculeGlucocorticoid receptor; Muscarinic M3; Beta-2 adrenergicReliable signal
NCT02465567: Rate of moderate/severe COPD exacerbations: PT010 (the trial's investigational triple therapy) reduced the rate by 24% vs glycopyrronium/formoterol fumarate (PT003) (p<0.001), and by 13% vs budesonide/formoterol fumarate (PT009) (p=0.003)
NCT02497001: Primary 1, FEV1 AUC0-4 at week 24, BGF MDI vs BFF MDI: LS mean difference 116 mL (95% CI 80 to 152; p<0.0001), met. Primary 2, change from baseline in morning pre-dose trough FEV1 at week 24, BGF MDI vs GFF MDI: 13 mL (95% CI -9 to 36; p=0.2375), missed. Separate Europe/Canada analysis over 24 weeks: FEV1 AUC0-4 vs BFF MDI +104 mL (95% CI 77 to 131; p<0.0001) and vs BUD/FORM DPI +91 mL (p<0.0001); trough FEV1 vs GFF MDI +22 mL (95% CI 4 to 39; p=0.0139), all met.
Dupilumab (Dupixent)ApprovedMonoclonal antibodyIL-4R-alphaPartial signal
NCT04456673: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.295 Exacerbation per participant-year (95% CI 1.048 to 1.6) | Dupilumab 300 mg q2w 0.859 Exacerbation per participant-year (95% CI 0.699 to 1.057)
NCT03930732: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.01 exacerbation per participant-year (95% CI 0.931 to 1.301) | Dupilumab 300 mg q2w 0.776 exacerbation per participant-year (95% CI 0.645 to 0.934)
Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signal
NCT02164513: Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001)
NCT02345161: Co-primary 1, trough FEV1 change to week 24 (ITT): +142 mL with FF/UMEC/VI vs -29 mL with budesonide/formoterol (LS mean difference 171 mL, 95% CI 148 to 194; P<0.001), met. Co-primary 2, SGRQ total score change to week 24 (ITT): -6.6 vs -4.3 units (LS mean difference -2.2, 95% CI -3.5 to -1.0; P<0.001), met. Supportive week-52 analyses in the extension subset: FEV1 difference 179 mL (95% CI 131 to 226; P<0.001); SGRQ difference -2.7 (95% CI -5.5 to 0.2; P=0.065), not significant.
Fluticasone Furoate / Vilanterol (Breo Ellipta)ApprovedSmall moleculeBeta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptorPartial signal
NCT01313676: Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Placebo — Dead: 275 Participants; Alive: 3832 Participants; Unknown: 4 Participants | Fluticasone Furoate 100 µg — Dead: 251 Participants; Alive: 3884 Participants; Unknown: 0 Participants | Vilanterol 25 µg — Dead: 265 Participants; Alive: 3853 Participants; Unknown: 0 Participants | Fluticasone Furoate/Vilanterol 100/25 µg — Dead: 246 Participants; Alive: 3874 Participants; Unknown: 1 Participants missed
Fluticasone Propionate / Salmeterol (Advair Diskus)ApprovedSmall moleculeGlucocorticoid receptor / Beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Glycopyrrolate / Formoterol Fumarate (Bevespi Aerosphere)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptorWeak signalFeatured results are non-efficacy only in this race
IpratropiumApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)not yet gradedNo reviewed efficacy summary in this indication
Ipratropium / AlbuterolApprovedSmall moleculeMuscarinic M3 receptor / Beta-2 adrenergic receptor (combination)not yet gradedNo reviewed efficacy summary in this indication
Mepolizumab (Nucala)ApprovedMonoclonal antibodyIL-5, Interleukin-5 (IL-5), ligand-neutralizingPartial signal
NCT04133909: Annualized Rate of Moderate or Severe Exacerbations (Up to Week 104): Mepolizumab 100 mg 0.8 Exacerbations per year (95% CI 0.7 to 0.91) | Placebo 1.01 Exacerbations per year (95% CI 0.89 to 1.15)
OlodaterolApprovedSmall moleculeBeta-2 adrenergic receptorReliable signal
NCT00782210: FEV1 AUC0-3h response at Day 85 (Week 12), difference from placebo: olodaterol 5 mcg +0.172 L (SE 0.019), P<0.0001; olodaterol 10 mcg +0.176 L (SE 0.019), P<0.0001 (study 1222.11, n=624).
NCT00796653: Week 24, olodaterol 5 and 10 ug vs placebo: FEV1 AUC0-3h +0.129 and +0.154 L (both p<0.0001); trough FEV1 +0.053 L (p=0.0055) and +0.069 L (p=0.0003); TDI focal score in this study +0.402 (p=0.1999) and +0.419 (p=0.1818), not significant; TDI in the combined analysis +0.509 (p=0.0270) and +0.525 (p=0.0203) (CT.gov posted results).
Olodaterol / Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Revefenacin (Yupelri)ApprovedSmall moleculeMuscarinic receptors (antagonist)Reliable signal
NCT05046795: Trough FEV1 on Day 85 (Baseline and Day 85): Revefenacin Inhalation Solution 175 mcg QD. 55.12 mL (Standard Error 23.974) vs Placebo Inhalation Solution QD. -95.78 mL (Standard Error 24.504)
NCT02459080: Study 0126: trough FEV1 change at day 85 vs placebo +79 mL with revefenacin 88 µg (p=0.0003) and +146 mL with revefenacin 175 µg (p<0.0001).
Roflumilast (Daliresp)ApprovedSmall moleculePDE4not yet gradedNo reviewed efficacy summary in this indication
Salmeterol (DISKUS)ApprovedSmall moleculeBeta-2 adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Tiotropium BromideApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Partial signal
NCT02172287: Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant.
Umeclidinium (Incruse Ellipta)ApprovedSmall moleculeMuscarinic acetylcholine receptor (M3)Reliable signal
NCT02184611: Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001)
NCT01387230: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 (Baseline and Day 85): Placebo -0.007 Liters (Standard Error 0.028) | UMEC 62.5 µg 0.12 Liters (Standard Error 0.0257) | UMEC 125 µg 0.145 Liters (Standard Error 0.0268)
Umeclidinium / VilanterolApprovedSmall moleculeMuscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptorReliable signal
NCT01777334: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115)
NCT01716520: Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour Forced Expiratory Volume in One Second (FEV1) Obtained Post-dose at Day 14 of Each Treatment Period (TP) by Response Type (Baseline and Day 14 of each treatment period (up to study day 83)): UMEC/VI 62.5/25 µg — Responder to UMEC, n=90, 90, 88: 0.337 Liters (Standard Error 0.0166); Responder to VI, n=99, 102, 100: 0.331 Liters (Standard Error 0.0148); Responder to Neither, n=36, 37, 36: 0.13 Liters (Standard Error 0.0243) vs UMEC 62.5 µg — Responder to UMEC, n=90, 90, 88: 0.216 Liters (Standard Error 0.0166); Responder to VI, n=99, 102, 100: 0.189 Liters (Standard Error 0.015); Responder to Neither, n=36, 37, 36: 0.077 Liters (Standard Error 0.0243) | VI 25 µg — Responder to UMEC, n=90, 90, 88: 0.201 Liters (Standard Error 0.0167); Responder to VI, n=99, 102, 100: 0.233 Liters (Standard Error 0.0147); Responder to Neither, n=36, 37, 36: 0.057 Liters (Standard Error 0.024)
AstegolimabPhase 3Monoclonal antibodyST2 (IL1RL1)Partial signal
NCT05595642: ARNASA (NCT05595642), primary endpoint annualized COPD exacerbation rate (AER) at 52 weeks: astegolimab showed a numerical 14.5% reduction vs placebo, not statistically significant missed
NCT05037929: Annualized COPD exacerbation rate reduced by a statistically significant 15.4% vs placebo at 52 weeks with every-two-weeks dosing
Beclomethasone Dipropionate / Formoterol FumaratePhase 3Small moleculeGlucocorticoid receptor; β2-adrenergic receptornot yet gradedNo reviewed efficacy summary in this indication
Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow)Phase 3Small moleculeGlucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination)Reliable signalNo reviewed efficacy summary in this indication
DepemokimabPhase 3Monoclonal antibodyIL-5not yet gradedNo reviewed efficacy summary in this indication
FelcorekibartPhase 3Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
HSK39004Phase 3Small moleculePhosphodiesterase 3 and Phosphodiesterase 4 (PDE3/PDE4)not yet gradedNo reviewed efficacy summary in this indication
LunsekimigPhase 3Antibody-derived scaffoldTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
REGEND001Phase 3Cell therapyAirway epithelial regeneration (autologous basal cells)Partial signalNo reviewed efficacy summary in this indication
Tezepelumab (Tezspire)Phase 3Monoclonal antibodyTSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizingnot yet gradedNo reviewed efficacy summary in this indication
TilrekimigPhase 3Multispecific antibodyIL-4/IL-13/TSLPnot yet gradedNo reviewed efficacy summary in this indication
TozorakimabPhase 3Monoclonal antibodyIL-33Partial signal
NCT06040086: Primary endpoint met: statistically significant reduction in the annualised rate of moderate-to-severe COPD exacerbations in former smokers and the overall population (MIRANDA, AstraZeneca, 2026-04-20).
NCT05158387: Primary endpoint met: tozorakimab reduced the annualised rate of moderate-to-severe COPD exacerbations vs placebo in former smokers and the overall population (TITANIA, 2026-03-27).
TQC3721Phase 3Small moleculePDE3/PDE4Partial signal
NCT06527144: Primary endpoint, change in peak FEV1 at week 4 vs placebo: 3 mg +100 mL (95% CI 41 to 159; P = .0011); 6 mg +147 mL (95% CI 93 to 201; P < .0001) (PACER-II, CHEST 2026).
StapokibartPhase 2/3Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
9MW1911Phase 2Monoclonal antibodyIL-33/ST2, ST2 (IL1RL1)Weak signalFeatured results are safety only in this race
AlvelestatPhase 2Small moleculeNeutrophil elastasePartial signal
NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively).
AZD6793Phase 2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
CM512Phase 2Multispecific antibodyTSLP + IL-13not yet gradedNo reviewed efficacy summary in this indication
DexpramipexolePhase 2Small moleculeEosinophil maturation/survival (mitochondrial)not yet gradedNo reviewed efficacy summary in this indication
GlasmacinalPhase 2Small moleculeAirway epithelial barrier integrityPartial signal
NCT05516316: Primary endpoint (BALF IL-8 after inhaled LPS challenge, 375 mg EP395 daily for 3 weeks vs placebo) not met. BALF IL-6, TNF-alpha, MIP-1alpha, MIP-1beta and MCP-1 were lower and IL-33, IL-8, IL-1beta, neutrophil elastase and myeloperoxidase higher with EP395 (none statistically significant). Serum SP-D rose with EP395 (mean 148.8 to 183.0 ng/mL at 24 h, p=0.0007) but not with placebo. missed
HRS-9821Phase 2Small moleculePDE3/PDE4Weak signalNo reviewed efficacy summary in this indication
OcankitugPhase 2Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
PBF-680Phase 2—Adenosine A1 receptornot yet gradedNo reviewed efficacy summary in this indication
PegtarazimodPhase 2PeptideComplement C1q / neutrophil effectors (myeloperoxidase, NETosis)not yet gradedNo reviewed efficacy summary in this indication
RademikibartPhase 2Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
RC1416Phase 2Multispecific antibodyIL-4 / IL-5 / IL-13not yet gradedNo reviewed efficacy summary in this indication
RSS0343Phase 2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
SolizmestrocelPhase 2Cell therapyRegenerative/anti-inflammatory (MSC)Weak signalNo reviewed efficacy summary in this indication
VerekitugPhase 2Monoclonal antibodyTSLP receptornot yet gradedNo reviewed efficacy summary in this indication
WIN378Phase 2Monoclonal antibodyTSLPnot yet gradedNo reviewed efficacy summary in this indication
XKH001Phase 2Monoclonal antibodyIL-25not yet gradedNo reviewed efficacy summary in this indication
KIT2014Phase 1/2PeptidePDE3/PDE4not yet gradedNo reviewed efficacy summary in this indication
APG808
Phase 1(overall)
Monoclonal antibodyIL-4R-alphanot yet gradedNo reviewed efficacy summary in this indication
BBT002Phase 1Multispecific antibodyIL-4Ralpha / IL-5not yet gradedNo reviewed efficacy summary in this indication
FrevecitinibPhase 1Small moleculeJAK1/2/3/TYK2Weak signalNo reviewed efficacy summary in this indication
GDC-6988Phase 1Small moleculeTMEM16A (Anoctamin-1) calcium-activated chloride channelnot yet gradedNo reviewed efficacy summary in this indication
GSK3862995Phase 1Monoclonal antibodyIL-33not yet gradedNo reviewed efficacy summary in this indication
PUR1800Phase 1Small moleculeNarrow-spectrum kinase (p38/Syk-family)not yet gradedNo reviewed efficacy summary in this indication
REGEND007Phase 1Cell therapyAirway basal layer stem cellsnot yet gradedNo reviewed efficacy summary in this indication
Ensifentrine / Glycopyrrolate
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
GSK6759821
—(overall)
RNA / oligonucleotide—not yet gradedNo reviewed efficacy summary in this indication
RG6527
—(overall)
Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
ItepekimabDiscontinuedMonoclonal antibodyIL-33Partial signal
NCT04701983: Annualized rate of moderate/severe AECOPD, reduction vs placebo at Week 52: 27% (every-2-week dosing arm), statistically significant primary endpoint met
NCT04751487: AERIFY-2 (NCT04751487), annualized rate of moderate/severe AECOPD exacerbations vs placebo at Week 52 (the primary-endpoint timepoint): 2% reduction with itepekimab every-2-weeks, 12% reduction with itepekimab every-4-weeks; neither reached statistical significance missed

Large race: only the 63 furthest-along competitors are listed; 1 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ohtuvayre (ensifentrine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (2)
March 2027 (1)
Phase 2Chronic Obstructive Pulmonary DiseaseActive not recruiting
Est. primary completion 2027-03-01 · NCT05270525 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2Non-cystic Fibrosis BronchiectasisRecruiting
Est. primary completion 2027-09-24 · NCT06559150 · CT.gov ↗
What to watch
2029 (1)
April 2029 (1)
Phase 3Chronic Obstructive Pulmonary DiseaseRecruiting
Est. primary completion 2029-04-29 · NCT07874815 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

January 2026Filing acceptedChina's NMPA accepts Nuance Pharma's NDA for Ohtuvayre (ensifentrine) in COPD
CN, NMPA · Nuance Pharma · Source ↗